ATE226447T1 - Anti-fas antikörper gegen rheumatische krankheiten - Google Patents

Anti-fas antikörper gegen rheumatische krankheiten

Info

Publication number
ATE226447T1
ATE226447T1 AT95115210T AT95115210T ATE226447T1 AT E226447 T1 ATE226447 T1 AT E226447T1 AT 95115210 T AT95115210 T AT 95115210T AT 95115210 T AT95115210 T AT 95115210T AT E226447 T1 ATE226447 T1 AT E226447T1
Authority
AT
Austria
Prior art keywords
fas
monoclonal antibody
antibodies against
rheumatic diseases
fas antibodies
Prior art date
Application number
AT95115210T
Other languages
English (en)
Inventor
Kusiki Nishioka
Shin Yoneyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE226447T1 publication Critical patent/ATE226447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95115210T 1994-09-27 1995-09-27 Anti-fas antikörper gegen rheumatische krankheiten ATE226447T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (1)

Publication Number Publication Date
ATE226447T1 true ATE226447T1 (de) 2002-11-15

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95115210T ATE226447T1 (de) 1994-09-27 1995-09-27 Anti-fas antikörper gegen rheumatische krankheiten

Country Status (9)

Country Link
US (1) US6086877A (de)
EP (1) EP0709097B1 (de)
KR (1) KR100371000B1 (de)
AT (1) ATE226447T1 (de)
CA (1) CA2158822C (de)
DE (1) DE69528624T2 (de)
DK (1) DK0709097T3 (de)
ES (1) ES2182860T3 (de)
PT (1) PT709097E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
ZA982371B (en) * 1997-03-21 1998-09-28 Sankyo Co Humanized anti-human fas antibody
EP1087993B1 (de) 1998-06-18 2008-04-02 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
MXPA01012206A (es) * 1999-05-24 2002-06-21 Sankyo Co Composiciones farmaceuticas que contienen anticuerpo anti-fas.
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
KR100944022B1 (ko) 2000-10-24 2010-02-24 순이찌 시오자와 만성 관절 류머티즘에 관여하는 게놈, 그 진단방법, 그발증 가능성의 판정방법, 이들의 검출용 진단키트 및 만성관절 류머티즘의 치료방법 및 치료약제
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8377444B2 (en) * 2008-08-01 2013-02-19 Axis Inc. Therapeutic agent or preventive agent for osteoarthritis
KR101684246B1 (ko) * 2010-01-29 2016-12-08 가부시키가이샤 아크시스 변형성 관절증 치료제를 포함하는 주사제
CN102811737A (zh) * 2010-01-29 2012-12-05 阿克西斯股份有限公司 骨关节炎治疗及预防药物组合物和上述组合物的制造方法
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
EP4276180B1 (de) 2012-01-12 2026-04-22 Endo Biologics Limited Clostridium histolyticum enzym
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
IL327169A (en) 2017-03-01 2026-05-01 Endo Ventures Ltd A method for assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
EP0510691B1 (de) * 1991-04-26 2004-11-03 Osaka Bioscience Institute Für ein menschliches Zelloberflächen-Antigen kodierende DNS
WO1993000917A1 (en) * 1991-07-05 1993-01-21 Seragen, Inc. Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
US5464833A (en) * 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
EP0723556A4 (de) * 1993-10-14 2003-03-19 Immunex Corp Fas antagonisten und ihre verwendungen
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
DE69528624D1 (de) 2002-11-28
ES2182860T3 (es) 2003-03-16
PT709097E (pt) 2003-03-31
CA2158822C (en) 2008-12-23
KR100371000B1 (ko) 2003-07-12
EP0709097A1 (de) 1996-05-01
KR960010024A (ko) 1996-04-20
EP0709097B1 (de) 2002-10-23
DK0709097T3 (da) 2003-02-24
DE69528624T2 (de) 2003-06-26
US6086877A (en) 2000-07-11
CA2158822A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
DE69528624D1 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
CY1122391T1 (el) Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια
TR200101205T1 (tr) ímmn hastalìklarìn tedavisi i‡in bir farmas”tik terkip
DE60143535D1 (de) Humane antikörper gegen cd40
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
EP1449850A4 (de) Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
Lupton et al. An unusual presentation of dermatomyositis: the type Wong variant revisited
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
DE68920624D1 (de) Menschlicher monoklonaler Antikörper, Hybridoma, das ihn herstellt, und pharmazeutisches Mittel.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
Wakabayashi et al. Long-term maintenance of golimumab effectiveness for injection spacing in rheumatoid arthritis patients with low disease activity who previously received other TNF inhibitors: minimum 2-year data from an observational study

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0709097

Country of ref document: EP